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Abstract
In order to maintain the level of healthcare that we now associate with developed countries,
innovation is imperative. Previous literature has shown that patients of chronic diseases
are often involved in the development of new treatments and medical devices to help
them cope with their health-condition. However the innovation developed by patients
is often ignored or even rejected. A possible approach to address this issue is to open
up healthcare innovation, by allowing patients and their caregivers to become themselves
active contributors to the innovation process. In this context, the aim of this dissertation
is to (1) quantify the extent to which patients and caregivers of rare diseases innovate, (2)
find demographic and non-demographic antecedents of patient innovation, and (3) assess
how the innovations impact the lives of patients.
A telephone survey was conducted with the main objective of measuring the extent to
which respondents had innovated, or not. 496 patients and caregivers of 250 rare diseases
responded to the survey. Following the data collection we performed a descriptive analysis
of the data and a multiple logistic regression to identify statistically relevant predictor
variables of patient innovators.
We found that 13% of respondents had innovated, and the variables that emerged
as predictors of being an innovator are: higher level of education, being unemployed or
looking after at home, being aware of the expenses with the disease, and Information
and Communication Technology readiness. On the other side, being single has a negative
impact on the propensity to innovate when compared with being married. Moreover, in a
7-point Likert scale measuring the quality of life of the patient, the innovations led to an
average improvement of 2.4 points.
Not only are patients developing completely new-to-the-market innovations, that are
improving the patients’ quality of life, but they also assume the risks of trying solutions
that had not yet been tested. This study suggests that the current producer-based and
paternalistic healthcare model should be revised, so patients are given the chance of playing
a more proactive role.




De forma a mantermos a saúde nos ńıveis que hoje associamos com páıses desenvolvidos,
a inovação é imperativa. Estudos anteriores revelaram que em vários casos pacientes de
doenças crónicas estão envolvidos no desenvolvimento de novos tratamentos e equipamen-
tos médicos que os ajudam a lidar com a sua condição. Contudo, as inovações desenvolvidas
por pacientes são frequentemente ignoradas ou até rejeitadas. Uma posśıvel solução para
superar esta crise de inovação seria deixar que pacientes e cuidadores se tornassem eles
próprios contribuidores ativos no processo de inovação. Deste modo o objectivo desta dis-
sertação é (1) quantificar até que ponto pacientes e cuidadores de doenças raras inovam,
(2) identificar antecedentes demográficos e não-demográficos de inovação por pacientes, e
(3) avaliar o modo como as inovações por pacientes afetam a vida dos pacientes.
Conduziu-se um questionário telefónico com o fim de determinar até que ponto os
entrevistados teriam inovado ou não. 496 pacientes e cuidadores de 250 doenças raras
responderam ao questionário. Após a recolha de dados, efetuámos uma análise descritiva
dos dados bem como uma regressão loǵıstica múltipla de forma a identificar variáveis
estatisticamente relevantes preditoras do fenómeno de inovação por pacientes.
Constatámos que 13% dos respondentes inovaram. As variáveis que emergiram como
preditoras foram: educação superior, estar desempregado ou ser doméstico, estar ciente
das despesas com a doença, utilização de tecnologias de informação. Por outro lado, ser
solteiro, quando comparado com ser casado, tem um impacto negativo na propensão para
inovar. Adicionalmente, numa escala de Likert de sete pontos que mediu a qualidade de
vida do paciente, denotou-se uma melhoria média de 2.4 pontos após a inovação.
Estes indiv́ıduos não apenas desenvolvem inovações que melhoram a qualidade de vida
dos pacientes, mas assumem também o risco de experimentar soluções que não foram ainda
testadas. Este estudo sugere que o atual modelo de saúde paternalista, cujo epicentro são
os produtores, deverá ser revisto tendo em vista a possibilidade de pacientes assumirem
um papel mais proactivo.
Palavras chave: inovação por utilizadores; inovação por pacientes; antedecentes de
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Health expenditure in OECD countries has grown at an average rate of 5% from 2000 to
2009 (OECD, 2013a). The GDP growth rate is less than half for the same period. The
result: health expenditure was responsible for an average slice of 9.5% of OECD mem-
bers’ GDP in 2011. Demand and expectations regarding healthcare have been increasing
astoundingly, yet in order to maintain the level of healthcare that we now associate with
developed countries enormous innovation is imperative. This task is far from easy to
accomplish. In the current healthcare system, healthcare innovation is an increasingly
lengthy and costly process. The average cost per new drug development to the point of
marketing approval was estimated on 802 million US$ (DiMasi et al., 2003). Bureaucracy
is not the least of worries, only to activate phase III trials 296 di↵erent process steps
are required (Dilts et al., 2009), thus, not surprisingly, the average time for clinical and
approval phases is 8.1 years (Kaitin and DiMasi, 2010).
In this context, it is important to think out of the box, and explore new forms of
innovating. Healthcare users, such as patients and their caregivers, due to their unique
knowledge about the diseases, can potentially become very powerful sources of innovation.
In point of fact research has already shown very successful innovation cases by patients and
their families (Oliveira et al., 2011; Oliveira, 2012; Habicht et al., 2013). We build upon
the user-innovation definition by von Hippel (2007), where patients are users of health-care
services. In that sense, patient innovators (PI) are individuals (patients or caregivers) who
have developed a new equipment, medical device, treatment, therapy, strategy, habit or
behavior with the intention of using (as opposed to sell) to treat or better cope with their
health condition (Shcherbatiuk, 2012).
The main objective of this dissertation is to empirically analyze the extent of patient
innovation as well as to identify its antecedents and evaluate its importance or impact. In
order to approach our problem statement, we will explore three main research questions:
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– We first need to know the extent to which patients are innovating: To what extent
are patients and their families innovating?
– Moreover, when it comes to a serious matter such as health, it is only logical to
encounter more conservative attitudes. In this sense, society needs to be convinced
of the utility of patient innovation, and that is why its impact should be measured:
What is the impact of patient innovation?
– Finally, if in fact the phenomenon is substantial and in order to benefit from their
advantages, there must be ways of identifying actual or potential patient innova-
tors, so the system can properly incorporate them: What factors contribute or
withhold patient innovation?
According to the European Organization for Rare Diseases, a disease is considered rare
if it a↵ects less than five in 10,000 persons. A total of 5,000 to 7,000 rare diseases have
been estimated, and they a↵ect 6% to 8% of Europe’s population (EURORDIS, 2005).
We have chosen to study the case of rare diseases in particular because although there
has been a growing interest and e↵ort to improve it, investigation for treatments in rare
diseases is still scarce and is a very challenging matter for researchers (Griggs et al., 2009).
In such an underserved market we expect a significant existence of patient innovation.
Through our contribution, we hope to emphasize the potential patient innovation has to
o↵er, and bring it to the attention of policymakers, regulators and healthcare professionals.
The following sections include a Literature Review (Chapter 2) with the scope of not
only positioning our research but also to present the main findings on this area up to date.
We will then proceed to determine our set of hypothesis as well as describe in detail the
data and methods used to address our research problem and questions in Chapter 3 –
Methodology. The results of our work will be presented in detail in Chapter 4. Lastly, we
will make a final comment on our results and highlight the limitations and future research
directions of our study in Chapter 5.
Chapter 2
Literature Review
In the Literature Review chapter we cover three main topics required to fully contextualize
this thesis. Section 2.1 discusses innovation, including its drivers (2.1.1) and what makes
it adopted (2.1.2). In section 2.2 user innovation will be presented, including its quan-
tification in di↵erent domains, its determinants, and importance. The subsection 2.2.1
covers the case of patient innovation and its potential. Finally in the last section, 2.3,
we will analyze the current healthcare model, including an overall picture of healthcare
innovation and the roles of the players involved in this industry.
2.1 Innovation
There are many suggested definitions for innovation. It comprises something new, origi-
nal or di↵erent that meets a market or society need (Frankelius, 2009), or simply a new
way of doing something (Porter, 1990). In a relatively popular definition, West (1990)
defines innovation as “the intentional introduction and application within a role, group,
or organization, of ideas, processes, products or procedures, new to the relevant unit of
adoption, designed to significantly benefit the individual, the group, or wider society”.
However, according to Baregheh et al. (2009) the existing definitions are in accordance
with the di↵erent disciplines, thus he proposed the following integrative definition of orga-
nizational innovation ‘the multistage process whereby organizations transform ideas into
improved products, services, or processes in order to advance, compete, and di↵erentiate
themselves successfully in their marketplace”. Without disagreement, the most important
requirements of an innovation are novelty, having an application component and, naturally,
having an intended benefit (Länsisalmi et al., 2006).
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Importance of innovation
The importance of innovation for competitiveness, e↵ectiveness and long term economic
growth of nations and organizations is unquestionably evident (Drucker, 1985; Porter,
1990; Wolfe, 1994), especially nowadays with increasingly international and globalized
competition (Schilling, 2005). In fact, Porter (1990) argued that in order to compete and
to sometimes gain competitive advantage, an investment in the creation and dissemination
of knowledge is essential.
For firms, innovation holds unquestionable importance, a study by N̊as and Leppãlahti
(1997) revealed that that non-innovating companies report lower profits, and that these
di↵erences are persistent in the future. Hult et al. (2004) confirmed that, independently
of the market instability, innovativeness, which is the capability of a firm to engage in
innovation, is a key determinant of business performance.
2.1.1 Drivers of innovation
There has always been a great deal of interest in understanding the determinants of in-
novation, which has not always been a subject of agreement. An important aspect to
bear in mind when performing such analysis, is that the best way to address e↵ects of
innovativeness and its antecedents is not through an unrealistic analysis of bivariate re-
lationships, but rather through a more integrated approach (Hult et al., 2004). In one
of the first studies about the drivers of innovation, Schmookler (1966) concludes that the
opportunities with more expected value will have a greater degree of innovation, thus be-
ing common to exploit and allocate inventive e↵ort to areas of higher expected demand
or profit expectations.
Focusing on organizational and individual level of innovation, Damanpour (1991) per-
formed a meta-analysis to test the relationships between innovation and thirteen of its
potential determinants as well as whether the assumption of instability in the results ac-
complished so far was valid, as there was substantial variance among studies. His study
resulted in ten statistically significant relations. Centralization, by disfavoring an environ-
ment of participation and communication, has a negative impact on innovation. Contrar-
ily, the following proved to have a positive e↵ect on innovation: specialization, functional
di↵erentiation, professionalism, managerial attitude toward change, technical knowledge
resources, administrative intensity, slack resources, and external communication and in-
ternal communication. Moreover the findings of his study suggested that these relations
were stable, and that the instability and variance of previous studies was due to sampling
error. Other boosters and key drivers of innovation at a company and individual level are
employees with a higher level of experience, or holding a university degree (Rao et al.,
2002).
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Sometimes innovation comes from sudden and spontaneous flashes in the minds of
innovators. These cases are rare though, and most innovation is intentional and comes
from determined and focused research of unexpected occurrences, incongruities, process
needs, and industry or market changes (Drucker, 1985). Moreover, there is the concept of
lead users, that are defined as individuals that experience needs ahead of the market and
expect to gain relatively high benefits by developing something to cope with that need,
thus being very prone to innovate (von Hippel, 1986; Herstatt and von Hippel, 1992).
Likewise, Morrison et al. (2000) argues innovation takes place among these so called lead
users, as long as it is cheaper to invent rather than search for a possible existing solution.
2.1.2 Innovation adoption
It is very di cult to tell what makes an innovation prosperous, i.e. adopted. There
has always been an enormous e↵ort in research to determine, standardize and predict
successful innovations, (Quinn, 1985; Rothwell, 1992; Denning and Dunham, 2010). As
Drucker (1985) debated “Innovation requires knowledge, ingenuity, and, above all else,
focus”, and more important than doing, the work of knowing is what really matters.
Porter (1990) defended that pressure, necessity and adversity will more likely lead an
innovation to success than the simple hope of gain. Nonetheless, the recommendations
we find in the literature not only diverge, but lead to contradictory directions (Denning,
2012).
The numbers speak for themselves, there are thirty thousand new products every year,
and only 10% of them succeed. On a business-like point of view, despite what seems natural
to assume, there is no relationship between the spending on Research and Development
(R&D) and financial performance of firms (Jaruzelski and Deho↵, 2008), as what counts
is not how much to spend but how to spend (Kandybin, 2009). According to Christensen
et al. (2005) one of the problems is the excessive e↵orts put on market segmentation
according to stereotyped customers and their needs, that result in “products that don’t
meet real people’s needs”. He suggests a more practical approach of rather identifying the
jobs people need to accomplish, and sell them in an improved way as a product or service.
Levitt (2002) argued that in a company very creative ideas will be mere deadweight if they
are not implementable. In the Information and Communication Technologies (ICT) field,
successful innovation depends on three basic points: a need, knowledge, and favorable
economics (Kalmanek, 2012).
Adoption and acceptance behaviour
When assessing the adoption and di↵usion of an innovation, on the one hand we can
analyze the perceived characteristics of an innovation that include: relative advantage,
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complexity, compatibility, trialability, and observability, and on the other hand we have
seven aspects to consider regarding the adopters: General Psychological Antecedents,
Context-Specific Psychological Antecedents; Meaning, The Adoption Decision, Concerns
in Pre-adoption Stage, Concerns during Early Use, Concerns in Established Users (Rogers,
2010). Agarwal and Prasad (1997) found that the perceived innovation characteristics of
visibility, compatibility and triability, together with external pressure are relevant when
explaining the acceptance behavior and usage of an innovation. However, the author
concludes that the variance in the likelihood of continued future use is only explained by
relative advantage and demonstrability.
One thing is for sure, in order to maximize society’s value through the innovation
process, there must be constant dialog between the innovators and the stakeholder groups,
including the non-traditional ones (Dormann et al., 2002). In this line of thought, Henry
Chesbrough developed the concept of open innovation that he defined as “a paradigm that
assumes that firms can and should use external ideas as well as internal ideas, and internal
and external paths to market, as the firms look to advance their technology” (Chesbrough,
2003, 2006)
2.2 User innovation
As mentioned in the previous section, for an innovation to succeed there must be a clear
link between the idea itself and the needs of those who will use the product or service.
That is why 60 to 80 % of important innovations in many industries were a response to
environmental factors, i.e. market needs, as opposed to technical opportunities (Utterback,
1974). Inevitably, not everybody sees their needs being met by manufacturers and firms.
There are many reasons behind unsatisfied consumer needs. For instance, firms generally
concentrate on the average consumer needs, rather than focusing on the exceptions, which
many times are indeed as extensive as the rule, leaving them underserved. Moreover,
there are needs that have not yet been identified, or whose development leads to low or no
expected profits. In this context, consumers might try to fulfill their desires by themselves.
Users thus start their own problem solving by altering, changing, or adapting existing
products or services, or even developing completely new ones. The result is a solution
developed by a user to satisfy his own needs, usually referred to as a user innovation (von
Hippel, 2007).
It has been documented that users, rather than manufacturers, are often the main
source of innovation, constituting the dominant driving force in some industries (von
Hippel, 1976, 1978; Thomke and von Hippel, 2002; von Hippel, 2007). von Hippel (1982)
hypothesized that these disparities are caused by di↵erences in the innovators’ capacities
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to appropriate the innovation benefit. In some cases, firms and manufacturers might also
be user innovators, when they use a product or a service as an input in their production
process. Users can be firms or individual consumers that benefit from using a given product
or a service (von Hippel, 2007).
Quantification of user innovation
Since the 70’s there has been a stream of research to identify, quantify, and study user
innovation. Although initially user innovation was considered a rare event, as research
progressed and more evidence is available, it became clear that it is in fact very common
and covers a long list of areas, e.g.:
1. Scientific instruments, with 77% of user innovation, and 80% in the case of major
innovations (von Hippel, 1976).
2. Semiconductor and electronic subassembly manufacturing equipment, with 63 % of
user innovation (von Hippel, 1977).
3. Printed circuit CAD software, with 24% of user innovation (Urban and von Hippel,
1988).
4. Pipe hanger hardware design, with 36% of user innovation (Herstatt and von Hippel,
1992).
5. Library information systems, with 26% of user innovation (Morrison et al., 2000).
6. Mountain biking equipment, with 19% of user innovation (Lüthje et al., 2003).
7. Outdoor consumer products, with 10% of user innovation (Lüthje, 2004).
8. Commercial and retail banking services, with 85% of user innovation (Oliveira and
von Hippel, 2011).
Determinants of user innovation
As the academic literature increasingly recognizes the phenomenon of user innovation, it
becomes increasingly relevant to understand the characteristics of this sort of innovator
as well as identify the determinants of such behavior so we can more easily identify users
who have innovated or will do so.
Just like in the general topic of innovation, if users expect a large profit as a result of
the development of a product, there will be a higher likelihood of innovation (Mansfield,
1968; Urban and von Hippel, 1988). Morrison et al. (2000) developed a study so as to
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identify variables that help discriminate between innovators and non-innovators in a way
that is easily captured via questionnaire. In this investigation seven variables were pointed
out, four of which were considered to have a positive e↵ect on the innovation by users.
First, the Leading Edge Status, a notion further explained in Morrison et al. (2004), which
is essentially the binary concept of “lead user” treated as a continuous variable through
the aggregation of four measures. Just like Herstatt and von Hippel (1992) and Franke
et al. (2006) have also pointed out, it has a positive impact on innovation. The other
three positive variables are 1) the technical capability of the user, 2) the fact that they
he/she is not able to find a suitably qualified third party that can be hired to carry out
the innovation, and 3) the level of need, that is used as a proxy of the benefit expected
from the innovation. Finally, if 1) the technical di culties of innovating are perceived as
more di cult, if 2) a producer, firm, supplier, etc. is receptive to perform the innovation
itself, especially free of charge, and if 3) producers, firms, suppliers, etc. have a policy
that discourages innovation by users, there will be a lower likelihood that innovation by
users will take place. In terms of demographic variables, there is a higher probability of
innovation in case the individual 1) is male, 2) holds an university degree, and 3) has a
technical profession or education, e.g. science or engineering (von Hippel et al., 2011). In
fact, if a person possesses these three characteristics the probability that he will innovate
is up to 260% higher.
Di↵usion of user innovation
One way to evaluate success and importance of an innovation is to consider the extent of
its di↵usion and adoption. In fact, as mentioned above, research suggests that users have
originally developed a relevant portion of innovations in several fields that were di↵used
by becoming the basis for many new commercial products and services.
When a di↵usion of an innovation is considered, there are several possible outcomes.
One is that the innovator becomes an entrepreneur and commercializes the solution (Shah
and Tripsas, 2007), or leaves the commercial part to another supplier or manufacturer. In
many cases, e.g. scientific instrument innovation, the user is the primary actor in most of
the innovation progress stages, leaving only the commercial di↵usion to the manufacturer
(von Hippel, 1976). Another outcome is that the innovator freely reveals the innovation to
a community, as in a well-known case of open source software. Nowadays many users are
able to get precisely what they need and properly develop their ideas, that later become
a complement for manufacturer innovation (von Hippel, 2005). This shift in the role of
consumers that were previously merely considered as “the market”, led to a new innovation
paradigm where consumers play an active role in the innovation process (Baldwin and von
Hippel, 2011).
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2.2.1 Patient innovation
A patient can be seen as a particular kind of user that expects significant benefits from
the use of solutions that help him/her cope with his/her condition.
Although this research area is still recent and scarce, previous work has already showed
how patients and their families have in fact innovated in the case of chronic diseases
(Oliveira et al., 2011; Shcherbatiuk, 2012; Oliveira, 2012; Habicht et al., 2013). For exam-
ple, close to 50% of the Treatments, Therapies & Medical Devices for Cystic Fibrosis were
developed by patients. Furthermore, patients and their families increasingly sense a need
to share their experiences and solutions with the remaining community. As the Informa-
tion & Communication Technologies (ICT) spread, a number of online communities and
blogs have flourished whereby patients are now sharing their experiences (Frydman, 2009).
Interestingly, many of these, especially in the cases of Orphan Diseases, are transforming
into Patient-driven research forums (Frydman, 2009; Wicks et al., 2010).
Potential of patient innovation for healthcare
As covered in the previous section, often driven by the desire to help the others patients
share their experiences and solutions. This is well depicted in the words of Habicht et al.
(2013),“In some cases the patients saved their own lives and end-up saving the lives of
others”. As the ICT become widely available, a number of online communities and blogs
have flourished. Patients are now able to share their experiences and personal, health-
related data1. Many of these communities, especially in the cases of orphan diseases,
are transforming into actual patient-driven research communities. Albeit the value and
knowledge created in such research forums, health suppliers and other stakeholders were
for long hesitant to include and consider their ideas (Frydman, 2009; Wicks et al., 2010).
There are signals of a positive change, as healthcare experts are increasingly acknowl-
edging the benefit and importance of the knowledge that patients and their families posses,
encouraging patient collaborations (Bessant et al., 2012). In terms of healthcare stake-
holders patients are the largest group, and they in fact possess expertize that not only is
unique but also sometimes di cult to transfer. Moved by an urgent sense of need, and
sometimes su↵ering from life-changing conditions, patients and their relative-caregivers
become a promising source of ideas on how to improve processes and medical devices, or
how to test new ways of treatment.
In their work Bessant et al. (2012) also refer to the benefits of an open innovation model
in healthcare innovation. A new paradigm, where patients could more easily express their
needs and collaborate from the beginning in the innovation process. By changing the
1
This is the case of Patients Like Me (http://www.patientslikeme.com).
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existing role of patients and medical practice, society’s health could benefit more and
faster, finally surpassing the current sense of healthcare innovation plateau. In fact, the
online platform PatientsLikeMe2 is a very promising example of an open innovation model
that brings patients to the center of medical system (Kuenne et al., 2011).
2.3 Current healthcare model
The World Heath Organization defines health as “a state of complete physical, mental and
social well-being and not merely the absence of disease or infirmity . . . The enjoyment of
the highest attainable standard of health is one of the fundamental rights of every human
being without distinction of race, religion, political belief, economic or social condition.”
(World Health Organization, 2006).
In most developed countries, the current healthcare setting is marked by three main
tendencies. Firstly the life expectancy at birth increase. It has risen more than 10 years
in the past 40 years to average values of 80 years in the OECD countries, 80.8 years
in Portugal, and 78.7 years in the US 3 (OECD, 2013b). The second is the ageing of
the populations, as a result of diminishing birth rates and the referred increase in life
expectancy. Many chronic conditions are age-related which means long-term heath care
for more people and longer. Finally, and also related to the previous two, spending on
health represents a very large and increasing share of both public an private expenditure.
From 2000 to 2009 the average growth rate of health expenditure in OECD countries
was circa 5%, which represents a growth substantially above the GDP growth. Although,
this tendency has stagnated since 2010, health expenditure represents 9.5% of the GDP
of OECD members, 10.2% in Portugal and 17.7% in the US, of which 72%, 66%, 48%
respectively, are public expenses 4 (OECD, 2013a). The situation seems unsustainable.
Healthcare innovation
Under such scenario, the urge for innovation in processes that lead to higher levels of
productivity, in new treatments, or a radical change in the whole healthcare system is
pointed as the solution (Bessant et al., 2012). The current healthcare model however
does not seem set to accept disruptive solutions that raise the quality of healthcare, but
nonetheless threaten the status quo of key stakeholders (Christensen et al., 2000).
Currently, healthcare innovation has become an increasingly lengthy and costly pro-




Values refer to the year of 2011.
4
Values refer to the year of 2011.
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that the average cost per new drug to the point of marketing approval is 802 million US$,
which when compared to previous studies revealed an annual increase real rate of 7.4%.
Regarding the length of the process, for standard cases5, the average times for clinical
phases is 6.5 years, and an additional 1.6 years in approval phase6, which summed repre-
sent a total time of 8.1 years (Kaitin and DiMasi, 2010). Partly this is due to an enormous
amount of bureaucracy involved, as a study by Dilts et al. (2009) has shown – in order to
activate phase III trials there are at least 239 working steps, 52 major decision points, 20
processing loops and 11 stopping points.
Despite this disappointing scenario, the investment in R&D has increased in the past
decades only the US Food and Drug Administration (FDA) approvals have not kept pace.
As a response to the situation Paul et al. (2010) argues that without “a dramatic im-
provement in R&D productivity, the pharmaceutical industry cannot sustain su cient
innovation”.
Involved players
Bessant et al. (2012) has identified and characterized the traditional five main players in
the healthcare industry: Regulators, Providers, Payers, Suppliers and Patients. Although
Regulators are the smallest group, they are the ones with greater influence as they set
regulatory guidelines, include ministries of health as well as national or regional commit-
tees. Payers include private and public health insurance, as well as government agencies.
Providers are all health professionals and medical experts providing care, and Suppliers
are on the one hand the ones innovating by developing new treatments, e.g. scientific
institutions as well as pharmaceutical and medical research companies, and on the other
hand the ones reselling such as pharmacies. Finally, largest and least with least influence
group, the Patients, which are the ones benefiting from care. This is represented in Figure
2.1.
The role of patients
In the previous context it becomes particularly interesting to understand to what extent
patients prefer an active role in their own care. In fact, for long there has been significant
research interest in understanding a patient’s desire to be informed, as well as the extent
to which patients wish to participate in medical treatment decision-making. These two
dimensions consist of measures of patients’ autonomy.
This has been a long debate, and authors have reached di↵erent conclusions in the case
of decision-making. Regarding the desire for information authors seem to agree that indeed
5
For priority cases, the total time is smaller by 1 year.
6
Values relate to the period of 2005-2009.
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Figure 2.1: Five main players in the healthcare system.
Adapted from Bessant et al. (2012).
most patients prefer to be more informed about the diseases and treatment alternatives
(Strull et al., 1984; Ende and Moskowitz, 1989; Deber et al., 1996; Levinson et al., 2005).
Nonetheless, there are studies stating that patients indeed do not prefer to be involved in
treatment decision-making Ende and Moskowitz (1989); Levinson et al. (2005), and other
arguing that most patients do not wish to hand over the treatment decision-making to their
physicians Strull et al. (1984); Deber et al. (1996). Moreover, patients’ desire for autonomy
in decision making is expected to increase farther 1) in the case of a life-threatening illness
(Degner and Sloan, 1992), 2) in case there is more than one treatment alternative and
3) for younger patients (Guadagnoli and Ward, 1998). A more recent study by Levinson
et al. (2005) found that 96% of patients preferred to be o↵ered choices and to be asked
their opinions, 52% do not wish to make final decisions and 44% rely only on information
provided by their physicians. Factors increasing decision-making aspirations include 1)
being female, 2) being more educated, 3) being healthier, and 4) being older up to 45
years. Factors decreasing decision-making desires include 1) being African-American and
Hispanic, and 2) being older than 45 years. As most of complementary and alternative
medicine (CAM) therapies are not accepted nor recommended by conventional medicine,
much use of its use might represent clear examples of patient’s autonomy in treatment
decision-making. More details on CAM are given in Appendix A.
Finally, there is an ongoing debate on the notion of “patient empowerment” in the
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health system. This idea includes topics as patient self-management, incentivizing patients
to reach more information with their doctors, and encouraging the involvement of patients
in treatment decision-making. Yet, there are still underlying assumptions, such as the
notion that “health care providers support patient e↵orts to gain control”, that require
further examination (Harris and Veinot, 2004).
Chapter 3
Methodology
In the methodology section we will initially relate our research problem and questions to
the approach we followed by determining our set of hypotheses (3.1). Hereafter we will
make a thorough description of the collected data (3.2) as well as the methods chosen to
test the hypotheses, and draw conclusions from the results (3.3).
3.1 Set of Hypotheses
The aims of our research are quantify innovation by patients, to identify its drivers and
evaluate its importance. In order to address this problem statement we defined three
research questions (RQ) and a hypothesis, whenever it is possible, for each of one of them.
In this section, we will present the hypotheses and their rational.
RQ1: To what extent are patients and their families innovating?
Previous research (Oliveira et al., 2011; Shcherbatiuk, 2012; Oliveira, 2012; Habicht et al.,
2013) already showed how patients and their families have in fact innovated and developed
a series of non-drug medical solutions with the intention of using them. The case of rare
diseases is particularly interesting for application of user innovation theory, as the market
is underserved and characterized by a relatively large group of unsatisfied users (patients)
(Griggs et al., 2009), with expectedly amplified needs. Accordingly, the hypothesis we will
explore is:
H1: There is considerable prevalence of patient innovation among patients of rare
diseases.
14
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RQ2: What is the impact of patient innovation?
For a patient innovation to be meaningful it has to either ameliorate the health-status, or
come as a solution to a problem. In other words, it should improve one’s life quality (Nuss-
baum et al., 1993). For that reason we will measure importance through the improvement
in life quality, thus hypothesizing:
H2: Patient innovation has a positive e↵ect on patients’ life quality.
RQ3: What factors contribute or withhold patient innovation?
Many antecedents of user innovation, demographic and non-demographic, have already
been suggested by Morrison et al. (2000) and von Hippel et al. (2011). In this study
we perform an exploratory analysis to verify to what extent some of these will hold in
the case of patient innovation, as well as test new variables including disease and health-
related ones. In table 3.1 of section 3.3.2 we will present all the tested variables and their
hypothesized e↵ect.
3.2 Data
Due to the specificity of our research problem we needed to collect a primary source of
data for the purpose of our exploratory research. The data used for this thesis are collected
within an international initiative for quantifying patient innovation, and we used the data
collected in Portugal. We performed telephone survey interviews to 496 patients (202, i.e.
41%) and caregivers (293, i.e. 59%)1 of rare diseases. We will now explain and describe
1) the survey design, 2) the data collection process, and innovation 3) validation and 4)
coding.
3.2.1 Survey design
The survey development and data collection was conducted in the context of a project
funded by the Peter Pribilla Foundation (Germany). Therefore the survey utilized builds
upon an international tested and validated online survey for visualizing patient innovation.
The original survey has been expanded to fit telephone interviews to patients of rare
diseases and their caregivers in Portugal. Although only part of them will be used for the
purpose of our research, the final survey has 73 questions in total. The survey has five
di↵erent sections, each with a set of questions that aim at a specific objective. These five
sections are:
1
The missing case is an interviewee that is both a patient and a caregiver. For the purpose of our
analysis this case will be treated as a patient.
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1. General questions about the disease and interviewee: The aim of the ques-
tions in this section is to identify the type2 of interviewee, as well as the disease,
and the implications at all levels (degree of limitations, satisfaction with the existing
treatment, and expenses) that the disease has in the interviewees’ life.
2. Questions about the innovation: The first question of this section will try to
identify if the interviewee has somehow developed a patient innovation. This question
is asked indirectly as “Have you ever developed, adapted, or used in a way that is
di↵erent from its original use, 1) a medical equipment, 2) a treatment, or therapy,
or 3) a behavior, or habit, or strategy to better cope with the disease?”, and an
example is given so as to enable an easier identification of a possible solution. In
case there is evidence of one or more innovations the person will be asked further
questions regarding these solutions, otherwise, the interviewee will pass directly to
the subsequent set of questions.
3. Questions for non-innovators: This set of questions is directed to interviewees
that do not provide a possible patient innovation. These questions will cover the
main reasons for not innovating as well as di culties expected should they attempt
to innovate.
4. Demographic questions: General demographic questions, including education
and field of study, economic and marital status, family size, and age.
5. ICT-related questions: The aim of these questions is to measure the degree of
openness to ICT. Interviewees are asked about their access to Internet and use of
social networks (Facebook or other disease-related), as well as if they would be willing
to join and share innovations in an online platform.
All the questions that were used for the purpose of our research are presented in detail
in Appendix B.
3.2.2 Data collection
The data collection process was performed in a partnership with Raŕıssimas – Associação
Nacional de Doenças Mentais e Raras3, a Portuguese association for both mental and rare
diseases. Information about potential contacts was obtained from their database and a
random sample of patients and caregivers was collected. All the interviews were carried
out by four employees of Raŕıssimas. These experts’ professional activity involves talking





CHAPTER 3. METHODOLOGY 17
telephone help-line for patients. They were therefore chosen to perform the interviews
so as to extract the highest possible level information, and maximize the response rate4.
Although there was a script with specific questions to follow, interviews were made in a
conversational style and thus took on average approximately 30 minutes.
3.2.3 Innovation validation
As von Hippel et al. (2011) asserted, it is essential to “eliminate false positives – claimed
innovations which were in fact not innovations (such as, I bought a piece of IKEA furniture
and put it together myself )”. For this reason we had to analyze all the collected innovations
individually and exclude false ones on the following grounds5:
1. Mistake: Innovations that should have been validated directly by the interviewer as
the patient either 1) said the innovation produced no result, or 2) said the solution
was recommended by the doctor.
2. Common sense: Obvious solutions fall on this category, that is perhaps best illus-
trated by examples: “The medication dried the skin, so I used a good moisturizer”,
or, “I removed slippery carpets to avoid falling”.
3. Not innovative: On the one hand, we have obvious cases of solutions that already
exist in the market, such as the use of a lace wig or a pillbox. Additionally, it
excludes cases of a known solution that produced usual benefits. An example would
be a solution as “practice of extracurricular activities to improve the general and
physical wellbeing and avoid deprecation”, or “physiotherapy to improve mobility”.
As opposed to these situations, a known solution that is used with a di↵erent purpose
and produces new results, such as the practice of martial arts, which was discouraged
by the doctor, leading to internal and external bleeding stopping, is considered
innovative.
3.2.4 Innovation coding
When it comes to user innovation in the field of healthcare the user not only has to
overcome the usual barrier of the process of innovation but also the psychological barrier
of being autonomous in terms of treatment decision-making due to the responsibility of
its inherent risks. Thus, we consider that to become a patient innovator, the person first
has to be active in the sense of assuming the responsibility of undertaking a treatment
beyond doctor recommendations. In this sense we developed a coding decision-model that
4
There were very few cases of interviewees rejecting to answer the questionnaire.
5
The examples that will be provided are real.
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is illustrated in Figure 3.1. The objective is to sort the solutions, in the following four
categories:
1. Passive: Solutions that are used as common treatment. These include non-innovators,
and solutions that were referred as being prescribed by the doctor.
2. Active: Existing solutions that are not always used as common treatment. An
example would be a drug that is only used in some countries. Additionally, it
includes existing solutions that are not recommended in common treatment, i.e.
those CAM treatments that are not yet accepted by conventional medicine.
3. Patient Innovator: Solutions that are completely new-to-the-market.
!
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with a new or 
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of using it to help 
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Figure 3.1: Innovation coding model.
The rational behind the model is that there are two main types of patients and care-
givers, those that are passive and do merely what the doctor advises, and those that are
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active. Active patients are to some extent autonomous in their treatment decision-making,
i.e. they seek alternatives and try other solutions by themselves. In this context, patient
innovations are innovative solutions that active patients or caregivers developed. This is


















Figure 3.2: Patient innovation represented as an active-innovative solution.
For the purpose of our analysis we are interested in studying the patient innovation
phenomenon, yet it is relevant to also analyze characteristics of active patients, as these
might be in a stage that anticipates becoming a patient innovator.
3.3 Methods
For the purpose of our data analysis we will use two methods: descriptive statistics (3.3.2),
specifically when addressing RQ 1 and RQ 2 and as a means to provide some information
regarding the collected data, and a multiple logistic regression for RQ 3, in order to identify
relevant predictors of patient innovation and active patients.
3.3.1 Descriptive Analysis
As was covered in the previous section, we quantified the number of patient innovations in
the sample, which resulted in two groups, patient innovators and non-patient innovators.
To test hypothesis 1 (“There is considerable prevalence of patient innovation among pa-
tients of rare diseases.”) we will quantify the proportion of patient innovation. Although
the populations have di↵erent characteristics, as we know a priori that patients have a
high need in a specific disease, we will verify if our results are in line with those of other
user innovation research findings (see section 2.2.
Hypothesis 2 (“Patient innovation will have a positive e↵ect on patients’ life quality.”)
only concerns the patient innovation cases. In the survey, these interviewees are asked
to rate life-quality on a 7-point Likert scale (“No life quality” to “Excellent life qual-
ity”)6 before and after the innovation. We will verify to what extent there is a perceived
6
We opted for a large scale as to measure improvement a high level of precision is required.
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improvement in life-quality due to the innovation.
3.3.2 Regression Analysis
Through RQ 3 (“What factors contribute or withhold patient innovation”) we aim at
identifying statistically relevant predictor variables of patient innovation, consequently
we performed a regression analysis. The dependent variable is dichotomous (being a
patient innovator or not), and therefore we used a logistic regression. The most important
outcome measure to interpret the logistic regression results is the odds ratio (OR), which
is an indicator of the change in odds of the independent variable occurring resulting from a
unit change in the predictor variable (Field, 2009). Thus for the purpose of our analysis we
will only consider predictor variables, those with P < 0.05, and a 95% confidence interval
(CI) > 1 for the OR. We will now describe in detail the model building process.
Model building
Our main dependent variable is the dichotomy of being or not a patient innovator. Nonethe-
less as mentioned previously, we will also perform the analysis for the case of a patient
being active or passive. Concerning the independent variables, according to Hult et al.
(2004) the best way to address e↵ects of innovativeness and its antecedents is not through
an unrealistic analysis of bivariate relationships, but rather through a more integrated
approach, thus we opted for a multivariate model. We entered the demographic predic-
tor variables in a first block and in a second block we included the remaining variables
together, as there was no apparent rational to separate them in di↵erent blocks. In Table
3.1 we summarize the independent variables of each block, as well as the hypothesized
e↵ect on patient innovativeness. In Appendix C we provide further information regarding
the measurement of each variable.
An additional analysis we will perform is the intercorrelation between the tested vari-
ables, as multicollinearity can be substantially problematic (Field, 2009). Although there
is no definite value above which a correlation7 is considered significant or too high, we will
consider the rule-of-thumb cut values defended by Cohen (1988): r = .10 (small e↵ect),
r = .30 (medium e↵ect) and r = .50 (large e↵ect).
7
We will use the Pearson product-moment correlation coe cient r.
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VARIABLE HYPOTHESIZED EFFECT
Age ***
Gender Male are more likely to innovate (Von Hippel et al., 2011).
Education Holding a university degree has a positive impact (Von Hippel et al., 2011).
Marital Status ***
Professional Situation ***
Number of years with the disease Positive effect, as the knowledge and experience with the disease is higher.
Type of disease: ICD-10 code ***
Relationship with the patient
Patients, as well as parents, due to the nature of the relationship, are more likely 
to innovate.
Limitations in daily life Positive effect, as the expected benefits of innovating will be higher.
Dissatisfaction with available treatment Positive effect, as the motivation to innovate is higher.
Expenses awareness Positive effect because a person that is aware of the expenses with the disease expresses concern and control about the disease and impacts it has in daily life.
ICT readiness Positive effect, due to the inherent acquired skills and knowledge.
*** Cases for which a priori we could not develop a theory
Block 1: Demographic variables.
Block 2: Non-demographic variables.
Table 3.1: Independent variables.
Chapter 4
Results
We will present the results of our exploratory research following the structure of our
research questions and proposed hypotheses. Thus we will first cover the encountered
prevalence of patient innovation (4.1), followed by the identification of its antecedents
(4.2) and finally the impact it has on patients’ quality of life (4.3).
4.1 Prevalence of patient innovation
From the 496 interviewees inquired, 255 (51%) reported they had developed at least one
possible solution. More specifically, 220 (44%) reported one solution, 33 (7%) reported two
solutions and 2 interviewees (0.4%) reported three solutions, thus totalizing 292 solutions
developed by 255 interviewees. Moreover, the 292 possible solutions were sorted into the
following types: 1) a medical equipment, 2) a treatment, or therapy, or 3) a behavior, or
habit, or strategy. The rarest type of solution was medical equipment (10%, 30 cases),
and the most common (50%, 146 cases) were treatments or therapies. In Table 4.1 we
summarize the information regarding all the solutions that were collected.
0 solu. 1 solu. 2 solu. 3 solu. total
241 220 33 2 496
30
Treatment or therapy 146





Table 4.1: Solutions before the validation. (N=496)
After the proposed solutions were validated, a total of 223 (76%) false positives were
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excluded due mainly to not being innovative (146 cases). Thus, only 69 solutions are pa-
tient innovations. Although only 24% were considered patient innovations, we nonetheless
recognized that 1791 (61%) of the provided solutions are examples of active patients’ ac-
tions, i.e. cases where patients decided to pursuit a given treatment beyond, and in many
cases against, the instructions given by the doctor. In this sense, after the validation was
performed, we encountered a total of 159 (32%) active patients in our sample, of which
62 (13%) are patient innovators as demonstrated in Figure 4.1. These findings allow us to
conclude that our first hypothesis, “There is considerable prevalence of patient innovation
among patients of rare diseases.”, is valid, as the proportion of patient innovation is in line
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Figure 4.1: Prevalence of patient innovation. (N=496)
4.2 Impact of patient innovation
Interviewers asked all the patients who reported an innovation to rate on a 7-point scale
(1 - non-existing to 7 - excellent), the quality of life of the patient before and after their
innovation took place. Figure 4.2 depicts the answers to these two questions regarding
each patient innovation. As is evident in the histogram, due to the shift to the left of the
“after” curve, there is a very strong improvement in the quality of life after the innovations.
Equally relevant is the fact that after the innovation the options 1 - non-existing quality
of life and 2 - very little quality of life were no longer chosen.
Furthermore, the average rate given to the quality of life of the patient before the
innovation was 2.92, i.e. close to 3 - little quality of life. With a 2.43 (an extra 83%) point
improvement the average quality of life reaches the value of 5.35 after the innovation,
staying between 5 - considerable and 6 - high. In fact, as is depicted in Figure 4.3 there
1
Including the patient innovations.
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Figure 4.2: Patients’ life quality before and after the innovation. (N=65)
are no cases of a decrease in the quality of life, and only seven innovations (11%) resulted in
the maintenance of the same level of life quality. Therefore, we find support for our second
hypothesis (“Patient innovation will have a positive e↵ect on patients’ life quality”), as
the innovations proved to have a significant and positive impact.
Total Relative percentage
Average life quality before the innovation (a) 2.92 55% (a/b)
Average life quality after the innovation (b) 5.35 183% (b/a)

















0! 1! 2! 3! 4! 5! 6!
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Figure 4.3: Post-innovation improvement in the quality of life of the patients. (N=65)
4.3 Antecedents of patient innovation
The results of the survey regarding the selected variables for the model are presented in
Appendix D. In Table D.1 we present the demographic variables, and in Table D.2 the
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non-demographic variables.
Concerning the intercorrelations between all the variables included and being a patient
innovator (PI), none are highly correlated (r   .50). From all the variables, the most
correlated pair is professional situation and age (r = .42 with P < .01). Regarding the
variables included in the model there are only two pairs of correlated variables, with
only a small e↵ect. The pairs are holding a university degree and professional situation
(r =  0.27, with P < .01), and ICT readiness and professional situation (r = 0.26, with
P < .01). Table 4.2 presents the intercorrelations between all the hypothesized variables
and patient innovativeness.
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13.
1.  Patient Innovator ***
2.  Age -0.05 ***
3.  Gender -0.02 0.08 ***
4.  Holding a university degree 0.07 -0.14** 0.04 ***
5.  Marital status -0.03 0.02 0.04 -0.02 ***
6.  Professional situation 0.03 0.42** 0.09* -0.27** -0.06 ***
7.  Years with the disease -0.01 0.16** -0.09* -0.03 0.06 0.15** ***
8.  ICD10 disease code -0.10* 0.13** 0.07 -0.01 0.03 0.07 -0.06 ***
9.  Relationship with the patient -0.04 0.00 0.04 0.12** 0.06 -0.03 -0.02 -0.11* ***
10.  Limitations in daily life 0.08 0.07 -0.01 -0.12** 0.00 0.19** 0.08 -0.03 0.08 ***
11.  Dissatisfaction with treatment 0.11* -0.10* -0.05 0.05 0.08 -0.08 0.04 -0.15** 0.01 0.27** ***
12.  Expenses awareness 0.20** -0.03 -0.03 0.03 -0.04 -0.05 -0.04 -0.15** -0.15** 0.14** 0.16** ***
13.  ICT readiness 0.13** -0.37** -0.04 0.26** -0.04 -0.36** -0.08 -0.20** 0.00 -0.11* 0.11* 0.03 ***
*   P < 0.05
**  P < 0.01
INTERCORRELATIONS BETWEEN HYPOTHESIZED VARIABLES
Table 4.2: Intercorrelations of hypothesized predictor variables.
There were both demographic and non-demographic variables predicting (with a P <
0.05) a person being a patient innovator in the multiple logistic regression. The demo-
graphic variables were: (1) holding a university degree, (2) being single, which has a nega-
tive impact, (3) being unemployed, and (4) looking after home as a profession. Regarding
non-demographic variables these were: (1) expenses awareness, and (2) ICT readiness.
Due to missing information in some data points (i.e., the answers “Prefer not to answer”
and “Non applicable”) only 437, of the 496, were included in the regression. Table 4.3
contains the odds ratio significance and 95% confidence intervals from all the variables
that arose as significant predictors.
The outcome of fitting an identical multiple logistic regression model to the active
patient dependent variable results in quite similar conclusions. As is represented in Table
4.4, from the six identified predictors of patient innovators, four are also predictors of
active patients or caregivers: (1) holding a university degree, (2) looking after home as a
profession, (3) expenses awareness, and (4) ICT readiness.
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SIG. OR OR 95% C.I.
Holding a university degree .036 1.88 (1.04 - 3.40)
Marital status: single .041 0.38 (0.15 - 0.96)
Professional situation: unemployed .047 2.12 (1.01 - 4.47)
Professional situation: looking after home .013 3.78 (1.33 - 10.7)
Expenses awareness .003 2.65 (1.40 - 4.99)
ICT readiness .021 1.73 (1.09 - 2.77)
SIG. OR OR 95% C.I.
Holding a university degree .000 2.19 (1.44 - 3.33)
Professional situation: looking after home .034 2.48 (1.02 - 5.73)
Expenses awareness .007 1.86 (1.18 - 2.92)
ICT readiness .002 1.52 (1.16 - 2.00)
SIGNIFICANT PREDICTORS OF PATIENT INNOVATION
SIGNIFICANT PREDICTORS OF ACTIVE PATIENTS
Table 4.3: Significant predictors of patient innovation in the multiple logistic regression.
SIG. OR OR 95% C.I.
Holding a university degree . 36 1.8 (1.04 - 3.40)
Marital status: single . 1 0.38 (0.15 - 0.96)
r f ssi l sit ti : unemployed . 47 2.12 ( .01 - 4.4 )
Prof s ion l situation: looking after home 1 3 78 33 10.7
Expenses awareness 03 2 65 40 4 99
ICT readiness .021 1.73 (1.09 - 2.77)
SIG. OR OR 95% C.I.
Holding a university degree . 00 .19 ( .44 - 3.3 )
Prof s ion l situation: looking after home 34 2 48 02 5 73
Expenses awareness 7 86 8 92
ICT readiness .002 1.52 (1.16 - 2.00)
SIGNIFICANT PREDICTORS OF PATIENT INNOVATION
SIGNIFICANT PREDICTORS OF ACTIVE PATIENTS
Table 4.4: Significant predictors of active patients in the multiple logistic regression.
As we show in Table 4.5, two of the variables from which no e↵ect was foreseen proved
to have some impact in the likelihood of a person being a patient innovator, these are (1)
marital status: single; and (2) professional situation: unemployed and looking after home.
Moreover, not all the individual hypothesized e↵ects of the variables were confirmed in the
regression. Five variables that were expected to have influence, in fact do not: (1) age,
(2) the number of years with the disease, (3) the relationship with the patient, (4) the
perceived limitations in daily life, and (5) the dissatisfaction with the available treatment.
Yet, there are possible interpretations for all the revealed e↵ects.
Let us first start with the demographic variables. In the case of gender, the usual
higher propensity of males to be user innovators is not verified. A possible explanation
is that when it comes to health issues, the need and perceived benefits of innovating are
equally distributed among genders. In fact, as demonstrated in Table 4.2 gender and PI
are not correlated (r = .02). Education, i.e. holding a university degree, as expected is an
antecedent of PI. This variable reveals that not only the subject is more likely to have the
required technical skills to innovate, but also that possesses a higher level of knowledge.
Being single, when compared to being married, was shown to have a negative impact. This
can possibly be explained by the fact that the person in question will have less support
as consequently feel more apprehensive about innovating. Finally, when compared to
employed, unemployed and looking after home individuals, are also more likely be a PI.
These cases have both one possible thing in common: more disposable time. Moreover,
these findings might also suggest that these cases include to a great extent either people
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VARIABLE HYPOTHESIZED EFFECT ACTUAL EFFECT STATUS
Age *** No effect. ***
Gender Positive effect for male. No effect. ✗
Education Positive effect. Positive effect. ✓
Marital Status *** Negative effect for: single. ***
Professional Situation ***
Positive effect for: unemployed 
and looking after home. ***
Number of years with the disease Positive effect. No effect. ✗
Type of disease: ICD-10 code *** No effect. ***
Relationship with the patient Positive effect for patients and parents. No effect. ✗
Limitations in daily life Positive effect. No effect. ✗
Dissatisfaction with available treatment Positive effect. No effect. ✗
Expenses awareness Positive effect. Positive effect. ✓
ICT readiness Positive effect. Positive effect. ✓
*** Cases for which a priori we could not develop a theory
Block 1: Demographic variables.
Block 2: Non-demographic variables.
Table 4.5: Actual e↵ect of the independent variables.
whose lives are highly conditioned by the disease or that, especially in the case of caregivers,
devote their life to the disease.
Considering the non-demographic variables, there at least two possible explanations
for the number of years with disease have proven to have no e↵ect on PI. Although a higher
level of expertise would be expectable, as time passes, there might also be the tendency
to (1) accept the disease and lose hope and (2) be more incapacitated. A higher level of
perceived limitations in daily life also revealed not to influence PI despite a higher benefit
of innovating was expected. An explanation for such an outcome may be the variable
itself, as a person whose life is more limited will less likely be prone to innovate. As for
the lack of relationship of a higher level of dissatisfaction with the available treatment and
the likelihood of innovation, possible explanations include (1) individuals that complain
the most are not necessarily those that will more likely take action, and (2) treatments
for rare diseases are very scarce, therefore most of the population is naturally dissatisfied,
and the e↵ect is mitigated.
Nevertheless, the outcomes of our analysis allow us to conclude that indeed the an-
tecedents of patient innovators include both demographic – (1) holding a university degree,
(2) being single, which has a negative impact, (3) being unemployed, and (4) looking after




In this chapter we will first provide a detailed analysis of the implications of our findings
(5.1). Than we will identify the existing limitations of our study (5.2) that, as will be
explained, will in some cases consist of opportunities for future research, a topic that will
be covered in section 5.3.
5.1 Implications of our research
As was presented, we observed a significant existence (32%) of patients and caregivers of
rare diseases that seek new solutions and start treatments beyond the recommendations of
the doctor, showing that to some extent they are autonomous in their treatment decision-
making. Among this group, some (13%) take the additional responsibility to go even
further and try completely new-to-the-market solutions, that they themselves developed
and that until that moment had not been tested. We refer to this group as patient
innovators, and the identification of its members is of the utmost importance for society
(Habicht et al., 2013). If the healthcare system is able to identify these individuals and
include them in a new and more collaborative healthcare research model, their innovations
will have the chance to reach a broader audience. In this way other patients facing the
same conditions will have the chance to choose between a wider set of medical equipment,
treatments and other solutions to better cope with their symptoms. Moreover, as was
suggested by our research, these patients might possibly increase their quality of life in a
very substantial way.
In this sense, the first conclusion to take from this dissertation is that there should
be an increased e↵ort to identify possible patient innovators. As we can see in Table 5.1
in the presence of all the identified predictor variables of our study, the likelihood that a
patient or caregiver will innovate is 320% higher than the likelihood of an average patient
or caregiver of doing so. These and other findings can be very helpful to address the issue
28
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percentage of PI increase
Whole sample 12.5% ***
Holding a university degree 15.3% 1.2
Marital status: single 7.4% 0.6
Professional situation: unemployed 16.7% 1.3
Professional situation: looking after home 23.3% 1.9
Expenses awareness 21.4% 1.7
ICT readiness 15.6% 1.3
Presence of all the variables 40% 3.2
PROPORTION OF PI IN THE PRESENCE OF PREDICTOR VARIABLES
Table 5.1: Percentage of patient innovators in the presence of the predictor variables.
of making the voices of PI’s being heard.
The clear positive impact that the innovations produced in the lives of the patients is
more than a su cient reason to acknowledge the great potential that these innovations
might have in the limited lives of yet so many underserved patients. In their constant
debate for reforms in the present health care system, policymakers, regulators and health
care professionals, should now have added reasons to at least consider a way in which
these innovations can be incorporated, tested and approved in the system.
In fact, another interesting aspect of our findings is the significant existence of active
patients, individuals that indeed are willing to risk more, maybe because in some cases
they do not have that much to lose. This suggests that our current healthcare system
is not only perhaps overprotective but paternalistic too. Paternalistic in the sense that
the pyramid of players in the healthcare system (Figure 2.1) gives no power at all to
their largest group: patients. Maybe the active individuals among that group could play
important roles, even if not that of innovating. They seem to be very willing to go beyond
mainstream medicine.
Building upon the three-phase new innovation paradigm developed by von Hippel et al.
(2011), we can conceive one interesting scenario where active patients somehow test and
evaluate (corresponding to phase 2 in Figure 5.1) the potential of patient innovations.
For instance, pharmaceuticals and other producers would then be able to produce these
innovations as soon as their potential became clearer. This is one clear situation where
recognizing active patients through the identification of their distinctive characteristics
can be so valuable.
Finally and in sum, there are numerous cases of patient innovation that are important
for society, as they were perceived to produce a positive impact on the quality of life of
patients. In this sense it may be beneficial to explore further how to identify, validate, im-
prove and di↵use these innovations and exploit this important innovative force of patients,
so others can take advantage of their benefits in the future.
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NEW INNOVATION PARADIGM
time!
Phase 1: Patient innovators develop the solutions for themselves.!
Phase 2: Active patients test and evaluate the solutions.!
Phase 3: When the potential is clear, producers 
enter the market.!
# of users 
using the 
solution!
Figure 5.1: Three-phase new innovation paradigm.
Adapted from von Hippel et al. (2011).
5.2 Limitations
There are some limitations in our work with implications that should be taken into account
when examining our results and conclusions. These limitations include:
– Although we consider our survey data very rich due to its comprehensiveness, the
sample size might, in some analysis, be small as there are many data combinations
with few occurrences. In this sense, our study would benefit from a bigger sample.
– The sample might not be, in some cases, representative of the population, as the
random sample was taken from the database of Raŕıssimas’ phone line for patient-
support. This data-base consists of individuals, both patients and caregivers, who
contacted Raŕıssimas.
– The validation of the patient innovations was based on internet research and com-
pleted internally, nonetheless a validation made by an expert panel, more specifically
by doctors, is a lacking requisite..
– The fact that we are using self-reported data which might be subject to distortion
and inaccuracy.
– The measurement of patients’ quality of life before and after the innovation is not
objectively measured and validated. Hence, this assessment may be biased due to
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consisting of a self-analysis of one’s innovation. This is a serious limitation that can
compromise the validity of the results, as self-reported measures are very susceptible
to biases (Hoskin, 2012).
– There is a significant amount of variance in the independent variables that is not
explain by the explanatory variables. Nonetheless this is common in any study
attempting to explain a complex human behavior.
– Just as in any regression analysis, we are not able to uncover sure causal relationships
between the variables.
Despite these limitations, we nonetheless consider that our research made some con-
tribution to the study of patient innovation.
5.3 Future research
Many of the identified limitations can be seen as future research opportunities, as our
study would undoubtedly be more conclusive if those limitations were overcome.
We studied rare diseases in particular because we expected to find there a more signif-
icant existence of PI among these patients. Therefore it would be interesting to analyze
if the results are maintained beyond the borders of orphan diseases. Similarly, we made
no distinction between patient innovators and caregiver innovators, and a cross-sectional
analysis could also be of interest in this point.
Regarding the study of the antecedents of patient innovators, there are a series of un-
accounted variables in our study, such as psychological traits, environmental conditions,
openness to experimentation, or even risk preferences that may contribute to the pre-
disposition of patients and caregivers to innovate. Future research should address these
variables.
Finally it is of the utmost importance to identify ways in which the safety and validity
of the innovations can be tested, thus this sort of models should be examined in future
studies.
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NCCAM1 defines complementary and alternative medicine (CAM) as “a group of diverse
medical and health care interventions, practices, products, or disciplines that are not
generally considered part of conventional medicine”. As most of CAM therapies are not
accepted nor recommended by conventional medicine, much use of its use might represent
clear examples of patient’s autonomy in treatment decision-making.
The use of CAM increased substantially in the 1990’s (Eisenberg et al., 1998) and in
2002 36% of US adults used some form of CAM, and 62% if we include prayer specifically
for health reasons (Barnes et al., 2004). This phenomenon led to an urge in conducting
scientific tests to prove CAM e cacy. There were, and still are, huge flaws and deficiencies
in the design and conduction of randomized controlled clinical trials (Fontanarosa and
Lundberg, 1998). This wave contributed to a lot of research in that direction, but although
in 2008 more than 7500 CAM trials were indexed in Medline the safety and e cacy of
many CAM therapies is still unknown (Chan, 2008).
1




1 - General Questions.
1. Does anyone in your family su↵er from a rare disease?
() Yes, me
() No
() Yes, a close relative or someone in my family (Indicate relationship:)
2. What is the rare disease?
3. For how long has this person su↵ered from that disease?
4. Is this condition limiting your life?
() No
() Yes
() Don’t know/ Prefer not to answer
() N/A
4.1 From 1 to 5 what is the weight that these limitations have in your life?
5. Are there flaws in the existing treatments/therapies/equipment?
() No
() Yes
() Don’t know/ Prefer not to answer
() N/A
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() Don’t know/ Prefer not to answer
() N/A
6.1 Can you specify a monthly expense?
7. Have you ever developed, adapted, or used in a way that is di↵erent from
its original use, a medical equipment, a treatment, or therapy, or a behavior,
or habit, or strategy to better cope with the disease?
() No
() Yes, a medical equipment (please describe)
() Yes, a Treatment/Therapy (please describe)
() Yes, a Behavior/ Habit/ Strategy (please describe)
2 - Questions about the innovation.




4 - Demographic questions.
28. Birth year of the patient?















() Looking after home
() Other:
34. Education level?




















37. Number of children?
38. Are you (or a member of your family) member of another rare disease
association?
() No
() Yes (If yes, which?):
5 - ICT Related Questions.
39. Do you have access to internet?
() No
() Yes
40. What social networks do you use?
() Facebook
() Social networks in the health area (please specify which):
41. We are developing a platform where patients of chronic and rare disease
can share among them experiences and solutions for their pathologies. Would





VARIABLE TYPE OF DATA MEASUREMENT UNDERLYING QUESTIONS
Age Categorical 5 Classes: 18-24; 25-34; 35-49 (control variable); 50-64; >64 ***
Gender Dichotomous *** ***
Education Dichotomous The dichotomous consists of holding (1) or not (0) a university degree.
1) A radio-button question about the level of education with six possible options: Primary, Secondary, 
Bachelor, Master, PhD, and Other.                                                                                                                              
Note: Though, we are interested in assessing the effect of holding a university degree (Bachelor, Master 
or PhD).
Marital Status Categorical 5 Classes: Married (baseline); Single; Divorced; Cohabitation; Widower 1) A radio-button question about the marital status with the five mentioned measurement options.
Professional 
Situation Categorical
6 Classes: Employed (baseline); Student; 
Unemployed; Retired; Looking after home; 
Other
1) A radio-button question about the professional situation with the six mentioned measurement options.
Years with the 





5 Classes: Congenital malformations, 
deformations and chromosomal abnormalities; 
Endocrine, nutritional and metabolic diseases; 
Diseases of the nervous system; Diseases of 
the musculoskeletal system and connective 
tissue; Other (baseline)
1) A text-box question asking to identify the disease.
Note 1: We manually sorted the disease into the ICD-10 codes. The ICD (International Statistical 
Classification of Diseases and Related Health Problems) is a medical classification list by the World 
Health Organization. There are 22 possible classes, of which 15 were found in our sample. As nearly 
85% of the diseases belong to only four classes, we created a class, “Other”, that gathered the 11 
classes with very low frequencies.




Categorical 5 Classes (“the patient is…”): Me; Son; Spouse; Father; Other (baseline)
1) A check-box question asking if the interviewee is a patient or a caregiver.
2) For caregivers only: a text-box to specify the relationship with the patient.




6-point scale: 1 (“No limitations”) to 6 (“Huge 
limitations”)
The 6-point scale is a result of the following questions:
1) A radio-button question asking if the interviewee consideres his life limited, with four options: yes, no, 
PNA and NA.






13-point scale: 1 (Completely satisfied) to 13 
(Completely dissatisfied with all types of 
offered treatment)
The 13-point scale is a result of the following questions:
1) A radio-button question asking if the interviewee considers there are flaws in the available treatments 
offered, with four options: yes, no, PNA and NA.
2) For those that answered “yes” only: three 5-point Likert scales to specify to what extent 1 (“No 
limitations”) to 5 (“Huge limitations”) there are limitations in: 1) Medical equipment, 2) treatments, or 
therapies, and 3) Behaviors, habits, or strategies.
Note: We removed three points to the grade due to option 1 “No limitations” in the Likert scales.
Expenses 
awareness Dichotomous
The dichotomous consists on the one hand of 
those that think the expenses with the disease 
are significant, simultaneously is able to 
specify a number (1), and the remaining cases 
(0), except for.
1) A radio-button question asking if the interviewee considers the expenses with the disease significant, 
with four options: yes, no, PNA and NA. 
2) A text-box question to specify the value. In this case we manually sorted the data into the following 
cases: does know (1), does not know (0), vague, i.e. “a lot” (0), and PNA.
Note: All the cases of NA and PNA, are excluded from the model.
ICT readiness Categorical 4-point scale: 1 (No ICT readiness) to 4 (High ICT readiness).
This scale results from attributing 1 point for each “yes” answer in the following three questions: 
1) Radio-button question about the use of internet (yes/no).
2) Radio-button question about the use of Facebook (yes/no).
3) Radio-button question about willingness to join a platform where patients share solutions (yes/no).
Note: As the three component measures are highly correlated (r > .50, except use of facebook and 
willingness to join the platform, that have r = .36)it is meaningful to consider only one ICT readiness 
construct (Morrison et al., 2000).
Block 1: Demographic variables.
Block 2: Non-demographic variables.
Table C.1: Independent variables measurement.
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Appendix D
Characteristics of the sample
DEMOGRAPHIC VARIABLES COUNT PERCENTAGE
Class: 18-24 13 3%
Class: 25-34 95 19%
Class: 35-49 222 45%
Class: 50-64 110 22%
Class: >64 56 11%
Female 419 84%
Male 77 16%
Holds university degree 190 38%

















Table D.1: Demographic characteristics of the survey sample. (N=496)
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Congenital malformations, deformations and chromosomal abnormalities 154 31%
Endocrine, nutritional and metabolic diseases 73 15%
Diseases of the nervous system 93 19%








Value = 0 86 17%
Value = 1 4 1%
Value = 2 37 7%
Value = 3 102 21%
Value = 4 136 27%
Value = 5 123 25%
N/A 6 1%






Prefered not to answer 21 4%
Consider expenses significant and can specify a value 173 35%
Don't consider expenses significant and/or cannot specify a value 323 65%
Value = 0 42 8%
Value = 1 44 9%
Value = 2 103 21%
Value = 3 307 62%
Expenses awareness
ICT readiness





Type of disease: ICD-10 code
Relationship with the patient
Dissatisfaction with available treatment





Table D.2: Non-demographic characteristics of the survey sample. (N=496)
